Abstract Body

Background: We are investigating the effectiveness of simeprevir (SMV) and sofosbuvir (SOF) in a real-world setting for patients with HIV/HCV co-infection.

Methods: Data on 80 HIV/HCV co-infected patients who initiated therapy between 12/2013 and 8/2014 were analyzed. Baseline and week-2 on-treatment data are reported. Week-4 and Week-12 post end-of-treatment responses were examined to determine the sustained virologic response (SVR) rates for patients who have completed therapy. Advanced fibrosis/cirrhosis was defined as a FIB-4 score ≥ 3.25. By 2/2015, SVR4 data will be available for all 80 patients. Data will also be available for additional co-infected patients (enrollment is on-going) and for a comparison cohort of patients with HCV mono-infection.

Results: Median age of the 80 HIV/HCV co-infected patients was 57 yr (range, 25-73 yr), 84% were male, 63% were white, 25% were black, and 38% were Hispanic. Nearly half (41%) were naïve to HCV treatment. Comorbidities were common: 50% had hypertension, 38% had depression, 16% had diabetes, 51% had advanced fibrosis/cirrhosis, and 8% had HCC. The baseline median HCV VL was 6.31 IU/mL (IQR: 5.9-6.7 IU/mL), platelet count was 135 x103/µL (IQR: 97-195 x103/µL), albumin was 3.9 g/dL (IQR: 3.6-4.2 g/dL), total bilirubin was 0.6 mg/dL (IQR: 0.5-1.0 mg/dL), and the CD4 count of the 54 patients with these data was 487 (IQR: 325-620); HIV VL was undetectable in 46/54 (85%). All but four patients were on HAART. Of 67 patients with genotype (gt) 1, 33 (39%) were on SOF/ribavirin (RBV), 15 (22%) were on SMV/SOF/RBV, and 19 (28%) were on SMV/SOF; 15 (22%) patients changed HAART to accommodate SMV. All 13 patients with gt 2 or 3 HCV were on SOF/RBV. At week-2, 66% of patients had data available. Of 26 gt 1 patients on SMV, HCV RNA was undetectable in 9 (35%). Of 27 patients on SOF/RBV, HCV RNA was undetectable in five (20%). SVR4 data are available for 28 gt 1 patients:15/15 (100%) on a SMV regimen achieved SVR4, as did 7/13 (54%) on SOF/RBV. SVR12 data are available for seven patients on SMV/SOF, all achieved SVR12. Only one gt 1 patient on SOF/RBV achieved SVR12.

Conclusions: SMV and SOF are important and highly effective DAAs for HIV/HCV co-infected patients, a group that was notoriously difficult to treat with interferon. SVR4 was achieved by all 15 patients treated with SMV/SOF (with or without RBV) who have reached the 4-week post end of treatment time point (DA031095, DK090317).

⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥⇥

⇥⇥

⇥

Genotype N (% of total) Median age, years (Range) FIB-4 score ≥3.25, n (%) Naïve, n(%) SVR4 rate
1
⇥⇥⇥
⇥⇥⇥SMV/SOF ± RBV
⇥⇥⇥
⇥⇥⇥SOF/RBV
67 (84%)
⇥⇥⇥
⇥⇥⇥34 (43%)
⇥⇥⇥
⇥⇥⇥33 (41%)
57 (25-73)
⇥⇥⇥
⇥⇥⇥56 (25-70)
⇥⇥⇥
⇥⇥⇥56 (34-73)
36/67 (54%)
⇥⇥⇥
⇥⇥⇥19/34 (56%)
⇥⇥⇥
⇥⇥⇥17/33 (51%)
26/67 (39%)
⇥⇥⇥
⇥⇥⇥16/34 (47%)
⇥⇥⇥
⇥⇥⇥10/33 (30%)
22/28 (79%)
⇥⇥⇥
⇥⇥⇥15/15 (100%)
⇥⇥⇥
⇥⇥⇥7/13 (54%)
2 7 (9%) 60 (46-63) 2/7 (29%) 2/7 (29%) 1/2 (50%)
3 6 (7%) 56 (54-69) 3/6 (50%) 4/6 (66%) 3/4 (75%)